Can aspirin resistance be clinically predicted in stroke patients?

Clinical Neurology and Neurosurgery

Volumn 110, Issue 2, 2008, Pages 110-116

  Seok, Jung Im ^a   Joo, In Soo ^b   Yoon, Jung Han ^b   Choi, Yun Jung ^b   Lee, Phil Hyu ^b   Huh, Kyoon ^b   Bang, Oh Young ^c  

^a Catholic University of Daegu   (South Korea)

^b Ajou University Medical CentSuwon   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Aspirin; Aspirin resistance; Ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOXANE B2;

ADULT; AGED; ARTICLE; ASPIRIN REACTION UNIT; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; ENTERIC COATED TABLET; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; KOREA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PARAMETER; PREDICTION; RAPID PLATELET FUNCTION ASSAY ASPIRIN SYSTEM; RISK FACTOR; STROKE; THROMBOCYTE FUNCTION; TREATMENT FAILURE; UNIVARIATE ANALYSIS; URINE LEVEL;

ADULT; AGED; ASPIRIN; BRAIN ISCHEMIA; COHORT STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE;

EID: 38149124125     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2007.09.005     Document Type: Article

References (31)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for preventive of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Grau A., Weimar C., Buggle F., Heinrich A., Goertler M., Neumaier S., et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke 32 (2001) 2559-2566
3. The Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998;279:1265-72.
4. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
5. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
6. Meyer B.C., Hemmen T.M., Jackson C.M., and Lyden P.D. Modified National Institute of Health Stroke Scale for use in stroke clinical trials: prospective reliability and validity. Stroke 33 (2002) 1261-1266
7. Bang O.Y., Kim J.W., Lee J.H., Lee M.A., Lee P.H., Joo I.S., et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 65 2 (2005) 296-298
8. Bang O.Y., Lee P.H., Yoon S.R., Lee M.A., Joo I.S., and Huh K. Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis. J Neurol Neurosurg Psychiatry 76 8 (2005) 1128-1134
9. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
10. Coleman J.L., Wang J.C., and Simon D.I. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point Care 3 (2004) 77-82
11. Malinin A., Spergling M., Muhlestein B., Steinhubl S., and Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 (2004) 295-301
12. Berrouschot J., Schwetlick B., Twickel G., Fischer C., Uhlemann H., Siegemund T., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113 (2006) 31-35
13. Albert M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushimata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
14. Gum P.A., Marchant K.K., Welsh P.A., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
15. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
16. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
17. Gum P.A., Marchant K.K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
18. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 113 (2004) 101-113
19. Tamminen M., Lassila R., Westerbacka J., Vehkavaara S., and Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes 27 (2003) 907-911
20. Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P., and Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984
21. Coma-Canella I., Velasco A., and Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101 1 (2005) 71-76
22. Shantsilar E., Watson T., and Lip G.Y. Aspirin resistance: what, why and when?. Thromb Res 119 (2007) 551-554
23. Mckee S.A., Sane D.C., and Deliargyris E.N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 88 (2002) 711-715
24. Wong S., Appleberg M., Ward C.M., and Lewis D.R. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg 27 (2004) 456-465
25. Faraday N., Becker D.M., Yanek L.R., Herrera-Galeano J.E., Segal J.B., Moy T.F., et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 98 (2006) 774-779
26. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., and Rothwell P.M. Screening for aspirin responsiveness after transient ischemic attack and stroke. Stroke 36 (2005) 1001-1005
27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;432:145-53.
28. Peterson J.G., Topol E.J., Sapp S.K., Young J.B., Lincoff A.M., and Lauer M.S. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 109 (2000) 371-377
29. Latini R., Tognoni G., Maggioni A.P., Baigent C., Braunwald E., Chen Z.M., et al., Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 35 (2000) 1801-1807
30. Narvaez I., Sagastagoitia J.D., Vacas M., Saez Y., Lafita M., Monica S., et al. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. Thromb Res 120 (2007) 671-677
31. Feher G., Koltai K., Papp E., Alkonyi B., Solyom A., Kenyeres P., et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 23 (2006) 559-567